Publications by authors named "Celso Luis Silva Oliveira"
Postpartum Treatment With Immunoglobulin Does Not Prevent Relapses of Multiple Sclerosis in the Mother.
Health Care Women Int
January 2016
Multiple sclerosis (MS) is a chronic, neurological, immune-mediated disease that can worsen in the postpartum period. There is no consensus on the use of immunoglobulin for prevention of disease relapses after delivery. We have shown that the controversial beneficial effect of immunoglobulin given immediately after birth could not be observed in patients with MS.
View Article and Find Full Text PDFMultiple sclerosis starting before the age of 18 years: the Brazilian experience.
Arq Neuropsiquiatr
October 2013
Article Synopsis
- The study investigates early onset multiple sclerosis (MS) in Brazilian patients diagnosed before age 18, highlighting the challenges in diagnosis and management.
- Data was collected retrospectively from 20 MS units across 11 states, resulting in 117 cases, with a mean onset age of 13.7 years and an average disease duration of 10 years.
- Overall, while some cases were severe, most patients with pediatric MS in Brazil exhibited relatively mild symptoms, with low disability levels and an average relapse rate of one episode every 2.5 years.
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Arq Neuropsiquiatr
October 2013
Article Synopsis
- Natalizumab is an effective treatment for multiple sclerosis (MS), but there's a risk of developing progressive multifocal leukoencephalopathy (PML) linked to JC virus (JCV) infection.
- A study aimed to determine how common JCV-DNA is among Brazilian MS patients treated with natalizumab, using real-time polymerase chain reaction (PCR) for detection.
- Out of 168 MS patients on natalizumab, 51.2% tested positive for JCV-DNA, contributing valuable data to the global understanding of JCV prevalence in MS patients.
Less than a hundred cases of pregnancies in women with neuromyelitis optica (NMO) have been published in the world. The aim of the present study was to add the Brazilian experience to this subject. Cases of women with NMO who became pregnant, or who developed NMO soon after pregnancy, were included.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the prevalence and characteristics of adverse events (AEs) in multiple sclerosis patients treated with natalizumab.
- Data was collected from 103 patients across 16 MS treatment centers in Brazil, revealing that 76.7% experienced no AEs, while 23.3% reported only mild AEs.
- Although the majority had minimal side effects, three significant AEs were recorded, including two fatalities, emphasizing the need for using natalizumab under specialized care despite its general safety profile.
Month of birth does not seem to interfere with the development of multiple sclerosis later in life in Brazilian patients.
Neuroepidemiology
December 2012
Background And Objective: Women with multiple sclerosis (MS) who intend to get pregnant are often advised to discontinue disease modifying therapy (DMT) prior to conception. This recommendation is not based on medical evidence and may interfere with disease control by immunomodulatory drugs. The present study was designed to help discuss the effect of DMT for MS on pregnancy and on disease course.
View Article and Find Full Text PDF